Literature DB >> 6776160

Blunting of furosemide diuresis by aspirin in man.

E Bartoli, S Arras, R Faedda, G Soggia, A Satta, N A Olmeo.   

Abstract

Experiments were performed on humans to study the blunting on the diuretic action of furosemide by prostaglandin synthetase inhibitors. Maximal water diuresis was instituted. At the peak of urine flow, clearance periods were performed during baseline conditions and repeated after the injection of aspirin and, subsequently, of furosemide. Control subjects did not receive aspirin. Urine flow rate (V), Cosm, and Na excretion (UNa) . V were significantly lower when the administration of the diuretic had been preceded by that of aspirin. In the absence of furosemide, however, aspirin did not influence renal hemodynamics nor Na and water reabsorption. Therefore, the same experimental protocol was repeated in paired experiments where each normal subject served as his own control, being studied twice, in the presence and absence of aspirin, respectively. The average changes in water and Na excretion induced by furosemide were not different when the patients were pretreated with aspirin as compared with those measured in the absence of prostaglandin inhibition. Changes occurring in individual experiments were significantly correlated (r = 0.95, P less than 0.01) with those in calculated furosemide clearance. Since aspirin, indomethacin, and meclophenamate are secreted by the organic acid transport system of the proximal tubule, competition for a common secretory mechanism, rather than prostaglandin inhibition, could mediate the blunting of furosemide diuresis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6776160     DOI: 10.1002/j.1552-4604.1980.tb01718.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

1.  Absence of a clinically significant interaction between theophylline and furosemide.

Authors:  U A Jänicke; B Krüdewagen; A Schulz; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 2.  Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics.

Authors:  L F Prescott
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

3.  Failure of indomethacin to impair the diuretic and natriuretic effects of the loop diuretic torasemide in healthy volunteers.

Authors:  E van Ganse; J Douchamps; F Deger; M Staroukine; A Verniory; A Herchuelz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Causes and treatment of oedema in patients with heart failure.

Authors:  Andrew L Clark; John G F Cleland
Journal:  Nat Rev Cardiol       Date:  2013-01-15       Impact factor: 32.419

Review 5.  [Eicosanoids and phospholipases].

Authors:  M Goerig; A J Habenicht; G Schettler
Journal:  Klin Wochenschr       Date:  1985-04-01

6.  Comparison of chlortenoxicam and indomethacin on frusemide-induced diuresis.

Authors:  A Hitoglou-Makedou; M Lawson; P Turner; H P Ferber
Journal:  Postgrad Med J       Date:  1989-11       Impact factor: 2.401

7.  Comparison of flupirtine and indomethacin on frusemide-induced diuresis.

Authors:  A Johnston; S J Warrington; P Turner; H Riethmuller-Winzen
Journal:  Postgrad Med J       Date:  1987-11       Impact factor: 2.401

8.  Experimental dissociation of the effects of prostaglandins on renal sodium and water reabsorption by cyclo-oxygenase inhibitors in the rat.

Authors:  E Bartoli; G F Branca; R Faedda; N A Olmeo; A Satta; G Soggia
Journal:  Br J Pharmacol       Date:  1982-07       Impact factor: 8.739

9.  An experimental study using sodium salicylate to reduce cochlear changes induced by furosemide.

Authors:  L P Rybak; W Santiago; C Whitworth
Journal:  Arch Otorhinolaryngol       Date:  1986

10.  Assessing Drug-Drug Interaction Potential among Patients Admitted to Surgery Departments in Three Palestinian Hospitals.

Authors:  Abdullah K Rabba; Ayeshe M Abu Hussein; Bayan K Abu Sbeih; Somaya I Nasser
Journal:  Biomed Res Int       Date:  2020-09-23       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.